MAP1LC3B — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1779869	1.00	11/20
SCHEMBL1780428	0.69	10/20
SCHEMBL1781059	0.59	10/20
SCHEMBL193131	0.44	10/20
SCHEMBL1780317	1.00	9/20
SCHEMBL1780581	1.00	7/20
SCHEMBL1781367	1.00	7/20
SCHEMBL1781754	1.00	7/20
SCHEMBL1097880	0.56	7/20
SCHEMBL423680	0.53	6/20
SCHEMBL1781501	0.52	6/20
SCHEMBL1424432	0.46	6/20
SCHEMBL955853	0.44	6/20
SCHEMBL476989	0.60	5/20
Lenalidomide (SCHEMBL1486013)	0.50	5/20
SCHEMBL1493251	0.48	5/20
SCHEMBL1424683	0.47	5/20
SCHEMBL960281	0.46	5/20
SCHEMBL1520716	0.41	5/20
SCHEMBL464519	0.54	4/20

Clinical trials — most relevant to MAP1LC3B by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Motor Function Efficacy of Pharmacological Treatments Targeting Energy Metabolism, in Parkinson's Patients	PHASE4	UNKNOWN
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING
Efficacy of Lithium Against Chemotherapy Induced Neutropenia in Breast Cancer Patients	PHASE3	COMPLETED
Effects of Cannabidiol (CBD) on the Activation of Autophagy and Inflammation Genes, Functional Consequences in Virologically Controlled HIV-infected Patients	PHASE2	COMPLETED
LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis	PHASE2	COMPLETED
FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer	PHASE1/PHASE2	COMPLETED
Clostridium Butyricum in Stenosing Crohn's Desease	PHASE1/PHASE2	NOT_YET_RECRUITING
Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease.	PHASE1	COMPLETED
Nilotinib in Huntington's Disease	PHASE1	UNKNOWN
Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma	PHASE1	WITHDRAWN
Far Infrared Irradiation for the Management, Control and Treatment of Frontotemporal Dementia	PHASE1	UNKNOWN
Role of Autophagy in Type 2 Diabetes Microvascular Dysfunction	EARLY_PHASE1	RECRUITING
Immunohistochemical Assessment of Programmed Death ligand1 and LC3B in GBM	nan	UNKNOWN
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Molecular Profile of the Evolution of Inclusion Body Myositis	nan	COMPLETED
Autophagy Bladder Cancer	nan	UNKNOWN
Generating Intervals of Reference FFor Early Life Brain Biomarkers.	nan	RECRUITING
Autophagy Markers in Endometrial Polyps	nan	COMPLETED
Correlation Between Autophagy-related Proteins and Inflammatory Markers in Hemodialysis Patients	nan	COMPLETED
Muscle Insulin Resistance in Aging (Mirage)	nan	ACTIVE_NOT_RECRUITING
Fasting, Exercise, and Diet to Activate Autophagy in Depression	nan	NOT_YET_RECRUITING
Time Course for Fasting-induced Autophagy in Humans	nan	WITHDRAWN
Evaluation of Serum Autophagic Biomarkers in the Acute Response to Walking and Cycling in Healthy Male Individuals	nan	ENROLLING_BY_INVITATION
Evaluation of a Novel PET Radioligand to Image OGA	nan	COMPLETED
Neurofilament Light- Chain in Ataxia Telangiectasia	nan	UNKNOWN
Effect of Non-chirurgical Periodontal Treatment on the Immune System From a Gender Perspective	nan	COMPLETED
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure	nan	COMPLETED
Autophagy/Apoptosis Balance in Placental Vascular Pathologies	nan	RECRUITING
Strong Evidence: Digitally Delivered Exercise in Older Adults	nan	ACTIVE_NOT_RECRUITING
Robotic vs. Traditional Verticalization in Patients With Severe Acquired Brain Injury: a Randomized Controlled Trial	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a MAP1LC3B binder may also engage these)

Protein	Name	Similarity
O41515	—	1.000	O41515 →
Q9CQV6	—	1.000	Q9CQV6 →
Q6XVN8	—	1.000	Q6XVN8 →
A6NCE7	—	1.000	A6NCE7 →
Q91VR7	—	1.000	Q91VR7 →
Q2HJ23	—	1.000	Q2HJ23 →
MAP1LC3A	Microtubule-associated protein 1 light chain 3 alpha	1.000	landscape →
A2XXR7	—	1.000	A2XXR7 →
Q9XEB5	—	1.000	Q9XEB5 →
Q6CMF8	—	1.000	Q6CMF8 →
Q2RBS4	—	0.999	Q2RBS4 →
Q23536	—	0.999	Q23536 →
Q5QFG1	—	0.998	Q5QFG1 →
Q62625	—	0.998	Q62625 →
Q8S927	—	0.998	Q8S927 →
Q8S926	—	0.998	Q8S926 →
P0C075	—	0.998	P0C075 →
Q9BY60	—	0.997	Q9BY60 →
Q8S925	—	0.997	Q8S925 →
Q755X2	—	0.997	Q755X2 →
Q9DCD6	—	0.997	Q9DCD6 →
Q6Z1D5	—	0.997	Q6Z1D5 →
Q9LRP7	—	0.997	Q9LRP7 →
Q8IJK2	—	0.997	Q8IJK2 →
GABARAP	Gamma-aminobutyric acid receptor-associated protein	0.996	landscape →
Q8MK68	—	0.996	Q8MK68 →
P0CO54	—	0.996	P0CO54 →
O94272	—	0.996	O94272 →
Q7XPR1	—	0.996	Q7XPR1 →
P38182	—	0.996	P38182 →